Novo Nordisk A/S (BCBA:NVO)
Argentina · Delayed Price · Currency is ARS | Market Cap | 312.90T -7.8% |
| Revenue (ttm) | 74.58T +5.6% |
| Net Income | 26.36T +4.8% |
| EPS | 5,930.67 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.87 |
| Forward PE | 15.27 |
| Dividend | 78.51 (0.74%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3,838 |
| Open | 10,770 |
| Previous Close | 10,630 |
| Day's Range | 10,570 - 10,770 |
| 52-Week Range | 8,940 - 11,920 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk launches Wegovy weight-loss pill in Germany
Novo Nordisk has launched its Wegovy pill in Germany, a spokesperson for the Danish drugmaker said on Tuesday, with investors keenly focused on the oral weight-loss treatment in light of intensifying...
GLP-1 weight loss drugs effective even at low starter doses
People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who graduate to h...
600,000 seniors have signed up for obesity drugs under new Medicare program
U.S. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz said on Monday that 600,000 seniors have signed up to receive GLP-1 weight loss medications in the first two months o...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell
Novo Nordisk shares fell on Thursday after Deutsche Bank downgraded the Danish drugmaker to Sell from Hold and lowered its price target, citing concerns over the company's growth prospects. The compan...
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason
Deutsche Bank downgrades Novo Nordisk, citing doubts over the drugmaker's ability to return to growth and navigate an impending patent cliff.
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns
The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes a...
Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
China drug regulator accepts Novo Nordisk's application for oral Wegovy
China's drug regulator has accepted Novo Nordisk's marketing application for the oral version of its weight-loss drug Wegovy, the Danish drugmaker said in a statement on Thursday.
Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump
Celon Pharma's experimental semaglutide product Reduzek, a generic alternative to Novo Nordisk's Wegovy and Ozempic, matched the blockbuster weight-loss drugs in an early-stage bioequivalence study,...
Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills
The study will run into 2028, testing two low doses of Wegovy, and follows the company disclosing recently that uptake of the pill had been particularly strong for its lowest doses across self-paying ...
Novo begins study to find lowest effective dose for Wegovy pill
Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study to find the lowest dose that still helps patients lose weight, according to a U.S. government databa...
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-tak...
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more.
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO Mike Doustdar defended the drugmaker's decision to sue rival Eli Lilly over its weight-loss drug advertising. "I am a big fan of competition.
Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America
Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.
PHARMA BETS: CEO turns to AI for next-generation drugs
Novo Nordisk President and CEO Mike Doustdar discusses the company's collaboration with artificial intelligence to accelerate drug discovery and development.
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin...
How Novo Nordisk's CEO Says He Is Shifting the Company's Perspective
Alan Murray recently wrote here about America's century-old companies that have survived by refusing to “let their past be an anchor.” They “heed the call to disrupt themselves, before they are disrup...
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.
Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
Danish drugmaker Novo Nordisk said on Wednesday it had won a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. from a district court in the Netherlands in a patent infringement...
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals
Chief Executive Mike Doustdar's comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Novo Nordisk Earnings Call Transcript: Q2 2026
Adjusted sales rose 7% in Q2 2026, led by strong GLP-1 and obesity franchise growth, despite lower prices and U.S. headwinds. The Wegovy pill saw rapid global uptake, and the company raised guidance while advancing its R&D pipeline and transformation savings.
Novo Nordisk Quarterly report: Q2 2026
Novo Nordisk has published its Q2 2026 quarterly earnings report on August 5, 2026.